MetaCap

Emergent BioSolutions (EBS) vs Lifecore Biomedical (LFCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lifecore Biomedical (LFCR) has outperformed Emergent BioSolutions (EBS) over the past year, losing 16.4% versus a loss of 49.7%. Over five years, LFCR leads with a -26.3% price change compared with -88.6% for EBS. Emergent BioSolutions is the larger company by market cap ($259.6 million vs $242.2 million), about 1.1 times the size, while Lifecore Biomedical is growing revenue faster (+0.5% vs -28.8%).

Emergent BioSolutions converts more of its revenue into profit, with a net margin of 7.1% versus -30.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EBS-49.70%LFCR-16.36%
+43%-9%-60%
Nov 21, 20251 yearNov 20, 2026
EBS-87.40%LFCR-32.67%
+37%-33%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EBS versus LFCR key metrics
MetricEBSLFCR
Share price$5.05$6.39
Market cap$259.65M$242.22M
1-day change-1.94%+0.31%
YTD return-59.14%-21.88%
1-year return-49.70%-16.36%
5-year return-88.58%-26.30%
Forward P/E4.83—
EPS (TTM)$-5.00$-1.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$742.90M$128.87M
Revenue growth (YoY)-28.81%+0.47%
Net income (latest FY)$52.60M$-38.72M
Gross margin56.09%31.27%
Operating margin13.47%-13.38%
Net margin7.08%-30.04%
52-week high$14.06$8.98
52-week low$4.36$3.63
Distance from 52-week high-64.08%-28.84%
Analyst consensusnonehold
Avg. price target upside+98.02%-1.72%
Average volume1.11M414.71K
Shares outstanding51.42M37.91M
Employees900382
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LFCR has outperformed EBS by 33.3 percentage points over the past year.
  • Emergent BioSolutions is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -30.0 cents for Lifecore Biomedical.
  • Lifecore Biomedical grew revenue faster in its latest fiscal year (+0.47% vs -28.81%).

About Emergent BioSolutions

EBS stock →

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees

About Lifecore Biomedical

LFCR stock →

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.

Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees

EBS vs LFCR FAQ

Which is bigger, Emergent BioSolutions or Lifecore Biomedical?

Emergent BioSolutions (EBS) is larger, with a market capitalization of $259.65M compared with $242.22M for Lifecore Biomedical (LFCR).

Which stock has performed better over the past year, EBS or LFCR?

LFCR returned -16.36% over the past 12 months, compared with -49.70% for EBS (price return, excluding dividends). Past performance does not predict future results.

Are Emergent BioSolutions and Lifecore Biomedical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons